Serum metabolomics sequencing
OtherSerum samples from the day before pre-treatment, day after pre-treatment, 2 weeks,4 weeks,8 weeks and 12 weeks after transplantation will be detected by metabolomics sequencing.
NCT Number: NCT06386445
This study aims to establish a cohort of 500 patients with hematological disease who undergoing allogeneic hematopoietic stem cell transplantation in the northwest region. All patients will be followed up at the outpatient clinic once a week after transplantation until 100 days after transplantation to observe the presence of acute graft versus host disease, acute kidney damage, and major cardiovascular adverse events. Serum samples from the day before pre-treatment, day after pre-treatment, 2 weeks,4 weeks,8 weeks and 12 weeks after transplantation will be detected by metabolomics sequencing.The primary objective is to explore the serum metabolic markers of acute graft versus host disease,acute kidney injury, and major adverse cardiac events within 100 days after transplantation,the secondary objective is to observe the high-risk factors for early complications.
Trial opening soon.
Get Notified0 year–65 year
All sexes
Observational
This study aims to establish a cohort of 500 patients with hematological disease who undergoing allogeneic hematopoietic stem cell transplantation in the northwest region. All patients will be followed up at the outpatient clinic once a week after transplantation until 100 days after transplantation to observe the presence of acute graft versus host disease, acute kidney damage, and major cardiovascular adverse events. Baseline characterisitcs of patients, including gender, age, disease type, transplant type, donor gender and age, pre-transplant baseline electrocardiogram, myocardial enzymology, renal function, and other indicators were recorded. Serum samples from the day before pre-treatment, day after pre-treatment, 2 weeks,4 weeks,8 weeks and 12 weeks after transplantation will be detected by metabolomics sequencing.The primary objective is to explore the serum metabolic markers of acute graft versus host disease,acute kidney injury, and major adverse cardiac events within 100 days after transplantation,the secondary objective is to observe the high-risk factors for early complications.
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Gender unlimited;
Normal heart and kidney function before transplantation;
Patients with indications for allogeneic hematopoietic stem cell transplantation.
Exclusion criteria
Individuals with a history of arrhythmia, heart failure, or PCI stent implantation prior to transplantation;
Patients with mental illness;
Those who are unwilling to sign informed consent.
Serum samples from the day before pre-treatment, day after pre-treatment, 2 weeks,4 weeks,8 weeks and 12 weeks after transplantation will be detected by metabolomics sequencing.
Time frame: within 100 days after transplantation
skin,liver and gastrointestinal acute graft versus host disease
Time frame: within 100 days after transplantation
Included AKI-R, AKI-I, and AKI-F ,the criteria for classification of AKI-R, AKI-I, and AKI-F are as follows: AKI-R was considered if there was an increase in serum creatinine to more than 1.5-fold of baseline value or a urinary output lower than 0.5 ml/kg/h for 6 h. AKI-I was considered if there was an increase in serum creatinine to more than 2-fold of baseline value or urinary output lower than 0.5 ml/kg/h for 12 h. AKI-F was considered if there was an increase in serum creatinine to more than 3-fold baseline value or urinary output lower than 0.3 ml/kg/h for 24 h.
Time frame: within 100 days after transplantation
cardiovascular mortality, coronary events, heart failure, atrial fibrillation/flutter
Contact information is provided by the study sponsor or research team.
First Affiliated Hospital Xi'an Jiaotong University
Other
Study on the Serum Metabolic Markers and Early Complications After Allogeneic Hematopoietic Stem Cell Transplantation in Hemaotological Diseases: Cohort Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07563010
Acute Myeloid Leukemia, Hematologic Diseases
View Trial DetailsNCT07358195
Chronic Disease, Disease Attributes
Boston, Massachusetts, United States
View Trial DetailsNCT07010068
Graft vs Host Disease, Immune System Diseases
View Trial DetailsNCT06468618
Mental Disorders, Nervous System Diseases
Boston, Massachusetts, United States
View Trial Details